MaxCyte sees Q4 core revenue between $6.6M and $6.7M
Source: SeekingAlpha
2026-01-12 08:16:08 ET
More on MaxCyte
- MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
- MaxCyte reports Q3 results
- MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
Read the full article on Seeking Alpha
For further details see:
MaxCyte sees Q4 core revenue between $6.6M and $6.7M
MaxCyte Inc.
NASDAQ: MXCT
MXCT Trading
5.77% G/L:
$1.10 Last:
1,382,133 Volume:
$1.04 Open:
MXCT Latest News
May 12, 2026 04:05:00 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCT Stock Data
$82,138,988
103,153,769
1.05%
195
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
